Literature DB >> 7519018

Systemic treatment of Kaposi's sarcoma: current status and future directions.

R C Lilenbaum, L Ratner.   

Abstract

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Cancer; Diseases; Hiv Infections; Literature Review; Neoplasms; Treatment; Viral Diseases; World

Mesh:

Substances:

Year:  1994        PMID: 7519018

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Risk of HIV/AIDS in China: subpopulations of special importance.

Authors:  H Z Qian; Z H Qian; S H Vermund; N Wang
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

2.  Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma.

Authors:  N Christeff; S Gharakhanian; N Thobie; E Wirbel; M T Dalle; D Costagliola; E A Nunez; W Rozenbaum
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 3.  A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.

Authors:  G Nasti; D Errante; S Santarossa; E Vaccher; U Tirelli
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

4.  Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression.

Authors:  R Köster; L M Blatt; M Streubert; C Zietz; H Hermeking; W Brysch; M Stürzl
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

Review 5.  Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.

Authors:  A J Coukell; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

6.  Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma.

Authors:  C Abels; S Karrer; W Bäumler; A E Goetz; M Landthaler; R M Szeimies
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.